Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | GSK3A | P49840 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792454 | 0.80 | ADRA2A (0.42) | MEN1KMT2ACCNB2CDK1CCNB1 | |
| SCHEMBL14506262 | 0.77 | KDM4E (0.41) | MEN1KMT2AKDM4EUSP2ALDH1A1 | |
| SCHEMBL16746134 | 0.76 | — | — | |
| SCHEMBL16746132 | 0.76 | — | — | |
| SCHEMBL12032781 | 0.75 | SLC40A1 (0.37) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL30335572 | 0.75 | MAPT (0.50) | MEN1KMT2AKDM4EUSP2ALDH1A1 | |
| SCHEMBL29463681 | 0.75 | MAPT (0.50) | MEN1KMT2AKDM4EUSP2ALDH1A1 | |
| SCHEMBL87693 | 0.75 | MAPT (0.50) | MEN1KMT2AKDM4EUSP2ALDH1A1 | |
| SCHEMBL12338365 | 0.73 | MAPT (0.48) | MEN1KMT2AKDM4EUSP2ALDH1A1 | |
| SCHEMBL15423518 | 0.73 | MAPT (0.54) | MEN1KMT2AKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9918990-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180009754-A1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-9399640-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-04-14 | — | — | US | disclosed |
| US-9120810-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BOARD INSTITUTE, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150148372-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | IDH1, IDH2, IDH3A | MEN1 781/4885KMT2A 1147/4885CCNB2 2562/4885 |
| US-20150148372-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | MEN1 2146/4885KMT2A 627/4885CCNB2 606/4885 |
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | MEN1 2146/4885KMT2A 627/4885CCNB2 606/4885 |
| US-20180009754-A1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | CYP8B1, CYP2C8, CYP2B6 | MEN1 4477/4885KMT2A 1365/4885CCNB2 3072/4885 |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | MEN1 2146/4885KMT2A 627/4885CCNB2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.